BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Srivastava RM, Lee SC, Andrade Filho PA, Lord CA, Jie HB, Davidson HC, López-Albaitero A, Gibson SP, Gooding WE, Ferrone S. Cetuximab-activated natural killer and dendritic cells collaborate to trigger tumor antigen-specific T-cell immunity in head and neck cancer patients. Clin Cancer Res. 2013;19:1858-1872. [PMID: 23444227 DOI: 10.1158/1078-0432.ccr-12-2426] [Cited by in Crossref: 201] [Cited by in F6Publishing: 134] [Article Influence: 22.3] [Reference Citation Analysis]
Number Citing Articles
1 Chen S, Li X, Chen R, Yin M, Zheng Q. Cetuximab intensifies the ADCC activity of adoptive NK cells in a nude mouse colorectal cancer xenograft model. Oncol Lett 2016;12:1868-76. [PMID: 27602116 DOI: 10.3892/ol.2016.4835] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
2 Carvalho MI, Silva-Carvalho R, Pires I, Prada J, Bianchini R, Jensen-Jarolim E, Queiroga FL. A Comparative Approach of Tumor-Associated Inflammation in Mammary Cancer between Humans and Dogs. Biomed Res Int 2016;2016:4917387. [PMID: 28053982 DOI: 10.1155/2016/4917387] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 3.0] [Reference Citation Analysis]
3 Vacchelli E, Aranda F, Eggermont A, Galon J, Sautès-Fridman C, Zitvogel L, Kroemer G, Galluzzi L. Trial Watch: Tumor-targeting monoclonal antibodies in cancer therapy. Oncoimmunology 2014;3:e27048. [PMID: 24605265 DOI: 10.4161/onci.27048] [Cited by in Crossref: 59] [Cited by in F6Publishing: 58] [Article Influence: 59.0] [Reference Citation Analysis]
4 Concha-Benavente F, Ferris RL. Oncogenic growth factor signaling mediating tumor escape from cellular immunity. Curr Opin Immunol 2017;45:52-9. [PMID: 28208102 DOI: 10.1016/j.coi.2017.01.004] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
5 Allen CT, Clavijo PE, Van Waes C, Chen Z. Anti-Tumor Immunity in Head and Neck Cancer: Understanding the Evidence, How Tumors Escape and Immunotherapeutic Approaches. Cancers (Basel) 2015;7:2397-414. [PMID: 26690220 DOI: 10.3390/cancers7040900] [Cited by in Crossref: 45] [Cited by in F6Publishing: 45] [Article Influence: 6.4] [Reference Citation Analysis]
6 Van der Jeught K, Xu HC, Li YJ, Lu XB, Ji G. Drug resistance and new therapies in colorectal cancer. World J Gastroenterol 2018; 24(34): 3834-3848 [PMID: 30228778 DOI: 10.3748/wjg.v24.i34.3834] [Cited by in CrossRef: 163] [Cited by in F6Publishing: 148] [Article Influence: 40.8] [Reference Citation Analysis]
7 Lo Nigro C, Ricci V, Vivenza D, Granetto C, Fabozzi T, Miraglio E, Merlano MC. Prognostic and predictive biomarkers in metastatic colorectal cancer anti-EGFR therapy. World J Gastroenterol 2016; 22(30): 6944-6954 [PMID: 27570430 DOI: 10.3748/wjg.v22.i30.6944] [Cited by in CrossRef: 41] [Cited by in F6Publishing: 36] [Article Influence: 6.8] [Reference Citation Analysis]
8 Muntasell A, Cabo M, Servitja S, Tusquets I, Martínez-García M, Rovira A, Rojo F, Albanell J, López-Botet M. Interplay between Natural Killer Cells and Anti-HER2 Antibodies: Perspectives for Breast Cancer Immunotherapy. Front Immunol 2017;8:1544. [PMID: 29181007 DOI: 10.3389/fimmu.2017.01544] [Cited by in Crossref: 31] [Cited by in F6Publishing: 29] [Article Influence: 6.2] [Reference Citation Analysis]
9 Polverini PJ, D'Silva NJ, Lei YL. Precision Therapy of Head and Neck Squamous Cell Carcinoma. J Dent Res 2018;97:614-21. [PMID: 29649374 DOI: 10.1177/0022034518769645] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 5.3] [Reference Citation Analysis]
10 Faden DL, Concha-Benavente F, Chakka AB, McMichael EL, Chandran U, Ferris RL. Immunogenomic correlates of response to cetuximab monotherapy in head and neck squamous cell carcinoma. Head Neck 2019;41:2591-601. [PMID: 30828910 DOI: 10.1002/hed.25726] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
11 Gruijs M, Ganzevles SH, Stigter-van Walsum M, van der Mast R, van Ostaijen-Ten Dam MM, Tuk CW, Schilham MW, Leemans CR, Brakenhoff RH, van Egmond M, van de Ven R, Bakema JE. NK Cell-Dependent Antibody-Mediated Immunotherapy Is Improved In Vitro and In Vivo When Combined with Agonists for Toll-like Receptor 2 in Head and Neck Cancer Models. Int J Mol Sci 2021;22:11057. [PMID: 34681717 DOI: 10.3390/ijms222011057] [Reference Citation Analysis]
12 Woller N, Gürlevik E, Ureche CI, Schumacher A, Kühnel F. Oncolytic viruses as anticancer vaccines. Front Oncol 2014;4:188. [PMID: 25101244 DOI: 10.3389/fonc.2014.00188] [Cited by in Crossref: 45] [Cited by in F6Publishing: 48] [Article Influence: 5.6] [Reference Citation Analysis]
13 Chai AWY, Yee PS, Cheong SC. Rational Combinations of Targeted Therapy and Immune Checkpoint Inhibitors in Head and Neck Cancers. Front Oncol 2022;12:837835. [PMID: 35372020 DOI: 10.3389/fonc.2022.837835] [Reference Citation Analysis]
14 Hoesli RC, Moyer JS. Immunotherapy for Head and Neck Squamous Cell Carcinoma. Curr Oral Health Rep 2016;3:74-81. [PMID: 27398287 DOI: 10.1007/s40496-016-0082-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
15 Shibaguchi H, Luo N, Shirasu N, Kuroki M, Kuroki M. Enhancement of antitumor activity by using a fully human gene encoding a single-chain fragmented antibody specific for carcinoembryonic antigen. Onco Targets Ther 2017;10:3979-90. [PMID: 28860806 DOI: 10.2147/OTT.S140174] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
16 Aranda F, Vacchelli E, Eggermont A, Galon J, Fridman WH, Zitvogel L, Kroemer G, Galluzzi L. Trial Watch: Immunostimulatory monoclonal antibodies in cancer therapy. Oncoimmunology 2014;3:e27297. [PMID: 24701370 DOI: 10.4161/onci.27297] [Cited by in Crossref: 84] [Cited by in F6Publishing: 84] [Article Influence: 10.5] [Reference Citation Analysis]
17 Qin X, Denton WD, Huiting LN, Smith KS, Feng H. Unraveling the regulatory role of endoplasmic-reticulum-associated degradation in tumor immunity. Crit Rev Biochem Mol Biol 2020;55:322-53. [PMID: 32633575 DOI: 10.1080/10409238.2020.1784085] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
18 Weidhaas JB, Harris J, Schaue D, Chen AM, Chin R, Axelrod R, El-Naggar AK, Singh AK, Galloway TJ, Raben D, Wang D, Matthiesen C, Avizonis VN, Manon RR, Yumen O, Nguyen-Tan PF, Trotti A, Skinner H, Zhang Q, Ferris RL, Sidransky D, Chung CH. The KRAS-Variant and Cetuximab Response in Head and Neck Squamous Cell Cancer: A Secondary Analysis of a Randomized Clinical Trial. JAMA Oncol 2017;3:483-91. [PMID: 28006059 DOI: 10.1001/jamaoncol.2016.5478] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 5.6] [Reference Citation Analysis]
19 Friedman J, Padget M, Lee J, Schlom J, Hodge J, Allen C. Direct and antibody-dependent cell-mediated cytotoxicity of head and neck squamous cell carcinoma cells by high-affinity natural killer cells. Oral Oncol 2019;90:38-44. [PMID: 30846174 DOI: 10.1016/j.oraloncology.2019.01.017] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 5.0] [Reference Citation Analysis]
20 Shevtsov M, Multhoff G. Immunological and Translational Aspects of NK Cell-Based Antitumor Immunotherapies. Front Immunol 2016;7:492. [PMID: 27891129 DOI: 10.3389/fimmu.2016.00492] [Cited by in Crossref: 18] [Cited by in F6Publishing: 26] [Article Influence: 3.0] [Reference Citation Analysis]
21 Shah A, Rauth S, Aithal A, Kaur S, Ganguly K, Orzechowski C, Varshney GC, Jain M, Batra SK. The Current Landscape of Antibody-based Therapies in Solid Malignancies. Theranostics 2021;11:1493-512. [PMID: 33391547 DOI: 10.7150/thno.52614] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 7.0] [Reference Citation Analysis]
22 Berrien-Elliott MM, Romee R, Fehniger TA. Improving natural killer cell cancer immunotherapy. Curr Opin Organ Transplant 2015;20:671-80. [PMID: 26414502 DOI: 10.1097/MOT.0000000000000243] [Cited by in Crossref: 30] [Cited by in F6Publishing: 23] [Article Influence: 5.0] [Reference Citation Analysis]
23 Boyerinas B, Jochems C, Fantini M, Heery CR, Gulley JL, Tsang KY, Schlom J. Antibody-Dependent Cellular Cytotoxicity Activity of a Novel Anti-PD-L1 Antibody Avelumab (MSB0010718C) on Human Tumor Cells. Cancer Immunol Res 2015;3:1148-57. [PMID: 26014098 DOI: 10.1158/2326-6066.CIR-15-0059] [Cited by in Crossref: 249] [Cited by in F6Publishing: 151] [Article Influence: 35.6] [Reference Citation Analysis]
24 Espinosa-Cotton M, Fertig EJ, Stabile LP, Gaither-Davis A, Bauman JE, Schmitz S, Gibson-Corley KN, Cheng Y, Jensen IJ, Badovinac VP, Laux D, Simons AL. A preliminary analysis of interleukin-1 ligands as potential predictive biomarkers of response to cetuximab. Biomark Res 2019;7:14. [PMID: 31346466 DOI: 10.1186/s40364-019-0164-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
25 Jie HB, Schuler PJ, Lee SC, Srivastava RM, Argiris A, Ferrone S, Whiteside TL, Ferris RL. CTLA-4⁺ Regulatory T Cells Increased in Cetuximab-Treated Head and Neck Cancer Patients Suppress NK Cell Cytotoxicity and Correlate with Poor Prognosis. Cancer Res 2015;75:2200-10. [PMID: 25832655 DOI: 10.1158/0008-5472.CAN-14-2788] [Cited by in Crossref: 158] [Cited by in F6Publishing: 112] [Article Influence: 22.6] [Reference Citation Analysis]
26 Srivastava RM, Trivedi S, Concha-Benavente F, Hyun-Bae J, Wang L, Seethala RR, Branstetter BF 4th, Ferrone S, Ferris RL. STAT1-Induced HLA Class I Upregulation Enhances Immunogenicity and Clinical Response to Anti-EGFR mAb Cetuximab Therapy in HNC Patients. Cancer Immunol Res 2015;3:936-45. [PMID: 25972070 DOI: 10.1158/2326-6066.CIR-15-0053] [Cited by in Crossref: 44] [Cited by in F6Publishing: 38] [Article Influence: 6.3] [Reference Citation Analysis]
27 Houot R, Kohrt H. CD137 stimulation enhances the vaccinal effect of anti-tumor antibodies. Oncoimmunology 2014;3:e941740. [PMID: 25610724 DOI: 10.4161/21624011.2014.941740] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
28 Xia W, Qi X, Li M, Wu Y, Sun L, Fan X, Yuan Y, Li J. Metformin promotes anticancer activity of NK cells in a p38 MAPK dependent manner. Oncoimmunology 2021;10:1995999. [PMID: 34745769 DOI: 10.1080/2162402X.2021.1995999] [Reference Citation Analysis]
29 Sconocchia G, Eppenberger S, Spagnoli GC, Tornillo L, Droeser R, Caratelli S, Ferrelli F, Coppola A, Arriga R, Lauro D, Iezzi G, Terracciano L, Ferrone S. NK cells and T cells cooperate during the clinical course of colorectal cancer. Oncoimmunology. 2014;3:e952197. [PMID: 25610741 DOI: 10.4161/21624011.2014.952197] [Cited by in Crossref: 61] [Cited by in F6Publishing: 61] [Article Influence: 7.6] [Reference Citation Analysis]
30 Davis RJ, Ferris RL, Schmitt NC. Costimulatory and coinhibitory immune checkpoint receptors in head and neck cancer: unleashing immune responses through therapeutic combinations. Cancers Head Neck 2016;1:12. [PMID: 31093342 DOI: 10.1186/s41199-016-0013-x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
31 Capuano C, Pighi C, Maggio R, Battella S, Morrone S, Palmieri G, Santoni A, Klein C, Galandrini R. CD16 pre-ligation by defucosylated tumor-targeting mAb sensitizes human NK cells to γc cytokine stimulation via PI3K/mTOR axis. Cancer Immunol Immunother 2020;69:501-12. [PMID: 31950225 DOI: 10.1007/s00262-020-02482-2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
32 Garrido G, Rabasa A, Sánchez B. Linking oncogenesis and immune system evasion in acquired resistance to EGFR-targeting antibodies: Lessons from a preclinical model. Oncoimmunology 2013;2:e26904. [PMID: 24498560 DOI: 10.4161/onci.26904] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
33 Magnes T, Melchardt T, Hufnagl C, Weiss L, Mittermair C, Neureiter D, Klieser E, Rinnerthaler G, Roesch S, Gaggl A, Greil R, Egle A. The influence of FCGR2A and FCGR3A polymorphisms on the survival of patients with recurrent or metastatic squamous cell head and neck cancer treated with cetuximab. Pharmacogenomics J 2018;18:474-9. [PMID: 28719596 DOI: 10.1038/tpj.2017.37] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
34 Khan Z, Epstein JB, Marur S, Gillespie MB, Feldman L, Tsai HL, Zhang Z, Wang H, Sciubba J, Ferris R, Grandis JR, Gibson M, Koch W, Tufano R, Westra W, Tsottles N, Ozawa H, Chung C, Califano JA. Cetuximab activity in dysplastic lesions of the upper aerodigestive tract. Oral Oncol 2016;53:60-6. [PMID: 26686755 DOI: 10.1016/j.oraloncology.2015.11.016] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.9] [Reference Citation Analysis]
35 Stephenson RM, Lim CM, Matthews M, Dietsch G, Hershberg R, Ferris RL. TLR8 stimulation enhances cetuximab-mediated natural killer cell lysis of head and neck cancer cells and dendritic cell cross-priming of EGFR-specific CD8+ T cells. Cancer Immunol Immunother 2013;62:1347-57. [PMID: 23685782 DOI: 10.1007/s00262-013-1437-3] [Cited by in Crossref: 52] [Cited by in F6Publishing: 43] [Article Influence: 5.8] [Reference Citation Analysis]
36 Ben-Shmuel A, Biber G, Barda-Saad M. Unleashing Natural Killer Cells in the Tumor Microenvironment-The Next Generation of Immunotherapy? Front Immunol 2020;11:275. [PMID: 32153582 DOI: 10.3389/fimmu.2020.00275] [Cited by in Crossref: 33] [Cited by in F6Publishing: 30] [Article Influence: 16.5] [Reference Citation Analysis]
37 Kwon Y, Kim M, Jung HS, Kim Y, Jeoung D. Targeting Autophagy for Overcoming Resistance to Anti-EGFR Treatments. Cancers (Basel) 2019;11:E1374. [PMID: 31527477 DOI: 10.3390/cancers11091374] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 7.3] [Reference Citation Analysis]
38 Vacchelli E, Pol J, Bloy N, Eggermont A, Cremer I, Fridman WH, Galon J, Marabelle A, Kohrt H, Zitvogel L, Kroemer G, Galluzzi L. Trial watch: Tumor-targeting monoclonal antibodies for oncological indications. Oncoimmunology 2015;4:e985940. [PMID: 25949870 DOI: 10.4161/2162402X.2014.985940] [Cited by in Crossref: 30] [Cited by in F6Publishing: 20] [Article Influence: 4.3] [Reference Citation Analysis]
39 Juliá EP, Amante A, Pampena MB, Mordoh J, Levy EM. Avelumab, an IgG1 anti-PD-L1 Immune Checkpoint Inhibitor, Triggers NK Cell-Mediated Cytotoxicity and Cytokine Production Against Triple Negative Breast Cancer Cells. Front Immunol 2018;9:2140. [PMID: 30294328 DOI: 10.3389/fimmu.2018.02140] [Cited by in Crossref: 41] [Cited by in F6Publishing: 41] [Article Influence: 10.3] [Reference Citation Analysis]
40 Rieckmann T, Kriegs M. The failure of cetuximab-based de-intensified regimes for HPV-positive OPSCC: A radiobiologists perspective. Clin Transl Radiat Oncol 2019;17:47-50. [PMID: 31206086 DOI: 10.1016/j.ctro.2019.05.003] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
41 Milcent B, Josseaume N, Riller Q, Giglioli I, Rabia E, Deligne C, Latouche JB, Hamieh M, Couture A, Toutirais O, Lone YC, Jeger-Madiot R, Graff-Dubois S, Amorim S, Loiseau P, Toubert A, Brice P, Thieblemont C, Teillaud JL, Sibéril S. Presence of T cells directed against CD20-derived peptides in healthy individuals and lymphoma patients. Cancer Immunol Immunother 2019;68:1561-72. [PMID: 31494742 DOI: 10.1007/s00262-019-02389-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
42 Xu MM, Pu Y, Zhang Y, Fu YX. The Role of Adaptive Immunity in the Efficacy of Targeted Cancer Therapies. Trends Immunol 2016;37:141-53. [PMID: 26778079 DOI: 10.1016/j.it.2015.12.007] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 3.2] [Reference Citation Analysis]
43 Ciardiello D, Famiglietti V, Napolitano S, Esposito L, Pietrantonio F, Avallone A, Maiello E, Cremolini C, Troiani T, Martinelli E, Ciardiello F, Martini G. Final results of the CAVE trial in RAS wild type metastatic colorectal cancer patients treated with cetuximab plus avelumab as rechallenge therapy: Neutrophil to lymphocyte ratio predicts survival. Clinical Colorectal Cancer 2022. [DOI: 10.1016/j.clcc.2022.01.005] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
44 Prat M, Salon M, Allain T, Dubreuil O, Noël G, Preisser L, Jean B, Cassard L, Lemée F, Tabah-Fish I, Pipy B, Jeannin P, Prost JF, Barret JM, Coste A. Murlentamab, a Low Fucosylated Anti-Müllerian Hormone Type II Receptor (AMHRII) Antibody, Exhibits Anti-Tumor Activity through Tumor-Associated Macrophage Reprogrammation and T Cell Activation. Cancers (Basel) 2021;13:1845. [PMID: 33924378 DOI: 10.3390/cancers13081845] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
45 Kansy BA, Shayan G, Jie HB, Gibson SP, Lei YL, Brandau S, Lang S, Schmitt NC, Ding F, Lin Y, Ferris RL. T cell receptor richness in peripheral blood increases after cetuximab therapy and correlates with therapeutic response. Oncoimmunology 2018;7:e1494112. [PMID: 30377562 DOI: 10.1080/2162402X.2018.1494112] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 3.5] [Reference Citation Analysis]
46 Naranjo-Gomez M, Lambour J, Piechaczyk M, Pelegrin M. Neutrophils are essential for induction of vaccine-like effects by antiviral monoclonal antibody immunotherapies. JCI Insight 2018;3:97339. [PMID: 29720574 DOI: 10.1172/jci.insight.97339] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
47 Castiello L, Aricò E, D'Agostino G, Santodonato L, Belardelli F. In situ Vaccination by Direct Dendritic Cell Inoculation: The Coming of Age of an Old Idea? Front Immunol 2019;10:2303. [PMID: 31611878 DOI: 10.3389/fimmu.2019.02303] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
48 Caratelli S, Sconocchia T, Arriga R, Coppola A, Lanzilli G, Lauro D, Venditti A, Del Principe MI, Buccisano F, Maurillo L, Ferrone S, Sconocchia G. FCγ Chimeric Receptor-Engineered T Cells: Methodology, Advantages, Limitations, and Clinical Relevance. Front Immunol 2017;8:457. [PMID: 28496440 DOI: 10.3389/fimmu.2017.00457] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 4.6] [Reference Citation Analysis]
49 Liu C, Zhang G, Xiang K, Kim Y, Lavoie RR, Lucien F, Wen T. Targeting the immune checkpoint B7-H3 for next-generation cancer immunotherapy. Cancer Immunol Immunother 2021. [PMID: 34739560 DOI: 10.1007/s00262-021-03097-x] [Reference Citation Analysis]
50 Hasegawa J, Sue M, Yamato M, Ichikawa J, Ishida S, Shibutani T, Kitamura M, Wada T, Agatsuma T. Novel anti-EPHA2 antibody, DS-8895a for cancer treatment. Cancer Biol Ther 2016;17:1158-67. [PMID: 27653549 DOI: 10.1080/15384047.2016.1235663] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 3.2] [Reference Citation Analysis]
51 Corogeanu D, Diebold SS. Direct and Indirect Engagement of Dendritic Cell Function by Antibodies Developed for Cancer Therapy. Clin Exp Immunol 2022:uxac026. [PMID: 35352109 DOI: 10.1093/cei/uxac026] [Reference Citation Analysis]
52 Capuano C, Pighi C, Battella S, De Federicis D, Galandrini R, Palmieri G. Harnessing CD16-Mediated NK Cell Functions to Enhance Therapeutic Efficacy of Tumor-Targeting mAbs. Cancers (Basel) 2021;13:2500. [PMID: 34065399 DOI: 10.3390/cancers13102500] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
53 Gildener-Leapman N, Ferris RL, Bauman JE. Promising systemic immunotherapies in head and neck squamous cell carcinoma. Oral Oncol 2013;49:1089-96. [PMID: 24126223 DOI: 10.1016/j.oraloncology.2013.09.009] [Cited by in Crossref: 71] [Cited by in F6Publishing: 66] [Article Influence: 7.9] [Reference Citation Analysis]
54 Kansy B, Aderhold C, Huber L, Ludwig S, Birk R, Lammert A, Lang S, Rotter N, Kramer B. Expression Patterns of CD44 and AREG Under Treatment With Selective Tyrosine Kinase Inhibitors in HPV+ and HPV- Squamous Cell Carcinoma. Cancer Genomics Proteomics 2020;17:579-85. [PMID: 32859636 DOI: 10.21873/cgp.20214] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
55 García-Foncillas J, Sunakawa Y, Aderka D, Wainberg Z, Ronga P, Witzler P, Stintzing S. Distinguishing Features of Cetuximab and Panitumumab in Colorectal Cancer and Other Solid Tumors. Front Oncol 2019;9:849. [PMID: 31616627 DOI: 10.3389/fonc.2019.00849] [Cited by in Crossref: 43] [Cited by in F6Publishing: 41] [Article Influence: 14.3] [Reference Citation Analysis]
56 Sun Y, Lu Y, Pen Q, Li T, Xie L, Deng Y, Qin A. Interferon gamma +874 T/A polymorphism increases the risk of cervical cancer: evidence from a meta-analysis. Tumour Biol 2015;36:4555-64. [PMID: 25649976 DOI: 10.1007/s13277-015-3100-4] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
57 Ferris RL. Immunology and Immunotherapy of Head and Neck Cancer. J Clin Oncol 2015;33:3293-304. [PMID: 26351330 DOI: 10.1200/JCO.2015.61.1509] [Cited by in Crossref: 319] [Cited by in F6Publishing: 185] [Article Influence: 45.6] [Reference Citation Analysis]
58 Shayan G, Kansy BA, Gibson SP, Srivastava RM, Bryan JK, Bauman JE, Ohr J, Kim S, Duvvuri U, Clump DA, Heron DE, Johnson JT, Hershberg RM, Ferris RL. Phase Ib Study of Immune Biomarker Modulation with Neoadjuvant Cetuximab and TLR8 Stimulation in Head and Neck Cancer to Overcome Suppressive Myeloid Signals. Clin Cancer Res 2018;24:62-72. [PMID: 29061643 DOI: 10.1158/1078-0432.CCR-17-0357] [Cited by in Crossref: 30] [Cited by in F6Publishing: 21] [Article Influence: 6.0] [Reference Citation Analysis]
59 Canossi A, Aureli A, Del Beato T, Rossi P, Franceschilli L, De Sanctis F, Sileri P, di Lorenzo N, Buonomo O, Lauro D, Venditti A, Sconocchia G. Role of KIR and CD16A genotypes in colorectal carcinoma genetic risk and clinical stage. J Transl Med. 2016;14:239. [PMID: 27519478 DOI: 10.1186/s12967-016-1001-y] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
60 Ferris RL, Lenz HJ, Trotta AM, García-Foncillas J, Schulten J, Audhuy F, Merlano M, Milano G. Rationale for combination of therapeutic antibodies targeting tumor cells and immune checkpoint receptors: Harnessing innate and adaptive immunity through IgG1 isotype immune effector stimulation. Cancer Treat Rev 2018;63:48-60. [PMID: 29223828 DOI: 10.1016/j.ctrv.2017.11.008] [Cited by in Crossref: 73] [Cited by in F6Publishing: 68] [Article Influence: 14.6] [Reference Citation Analysis]
61 Ando M, Nagata K, Nihira K, Suzuki Y, Kanda Y, Adachi M, Kubota T, Kameyama N, Nakano M, Ando H, Yamano K, Ishii T, Nakai R, Nakamura K. Potent Therapeutic Activity Against Peritoneal Dissemination and Malignant Ascites by the Novel Anti-Folate Receptor Alpha Antibody KHK2805. Transl Oncol 2017;10:707-18. [PMID: 28710915 DOI: 10.1016/j.tranon.2017.06.007] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
62 Kohrt HE, Tumeh PC, Benson D, Bhardwaj N, Brody J, Formenti S, Fox BA, Galon J, June CH, Kalos M, Kirsch I, Kleen T, Kroemer G, Lanier L, Levy R, Lyerly HK, Maecker H, Marabelle A, Melenhorst J, Miller J, Melero I, Odunsi K, Palucka K, Peoples G, Ribas A, Robins H, Robinson W, Serafini T, Sondel P, Vivier E, Weber J, Wolchok J, Zitvogel L, Disis ML, Cheever MA; Cancer Immunotherapy Trials Network (CITN). Immunodynamics: a cancer immunotherapy trials network review of immune monitoring in immuno-oncology clinical trials. J Immunother Cancer 2016;4:15. [PMID: 26981245 DOI: 10.1186/s40425-016-0118-0] [Cited by in Crossref: 38] [Cited by in F6Publishing: 34] [Article Influence: 6.3] [Reference Citation Analysis]
63 Moy JD, Moskovitz JM, Ferris RL. Biological mechanisms of immune escape and implications for immunotherapy in head and neck squamous cell carcinoma. Eur J Cancer 2017;76:152-66. [PMID: 28324750 DOI: 10.1016/j.ejca.2016.12.035] [Cited by in Crossref: 50] [Cited by in F6Publishing: 51] [Article Influence: 10.0] [Reference Citation Analysis]
64 Li J, Srivastava RM, Ettyreddy A, Ferris RL. Cetuximab ameliorates suppressive phenotypes of myeloid antigen presenting cells in head and neck cancer patients. J Immunother Cancer 2015;3:54. [PMID: 26579227 DOI: 10.1186/s40425-015-0097-6] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 3.4] [Reference Citation Analysis]
65 Haen SP, Schmiedel BJ, Rothfelder K, Schmied BJ, Dang TM, Mirza N, Möhle R, Kanz L, Vogel W, Salih HR. Prognostic relevance of HER2/neu in acute lymphoblastic leukemia and induction of NK cell reactivity against primary ALL blasts by trastuzumab. Oncotarget 2016;7:13013-30. [PMID: 26887048 DOI: 10.18632/oncotarget.7344] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
66 Hulett TW, Jensen SM, Wilmarth PA, Reddy AP, Ballesteros-Merino C, Afentoulis ME, Dubay C, David LL, Fox BA. Coordinated responses to individual tumor antigens by IgG antibody and CD8+ T cells following cancer vaccination. J Immunother Cancer 2018;6:27. [PMID: 29618380 DOI: 10.1186/s40425-018-0331-0] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
67 Mazorra Z, Lavastida A, Concha-Benavente F, Valdés A, Srivastava RM, García-Bates TM, Hechavarría E, González Z, González A, Lugiollo M, Cuevas I, Frómeta C, Mestre BF, Barroso MC, Crombet T, Ferris RL. Nimotuzumab Induces NK Cell Activation, Cytotoxicity, Dendritic Cell Maturation and Expansion of EGFR-Specific T Cells in Head and Neck Cancer Patients. Front Pharmacol 2017;8:382. [PMID: 28674498 DOI: 10.3389/fphar.2017.00382] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 3.2] [Reference Citation Analysis]
68 Maron SB, Alpert L, Kwak HA, Lomnicki S, Chase L, Xu D, O'Day E, Nagy RJ, Lanman RB, Cecchi F, Hembrough T, Schrock A, Hart J, Xiao SY, Setia N, Catenacci DVT. Targeted Therapies for Targeted Populations: Anti-EGFR Treatment for EGFR-Amplified Gastroesophageal Adenocarcinoma. Cancer Discov 2018;8:696-713. [PMID: 29449271 DOI: 10.1158/2159-8290.CD-17-1260] [Cited by in Crossref: 62] [Cited by in F6Publishing: 37] [Article Influence: 15.5] [Reference Citation Analysis]
69 Trivedi S, Jie HB, Ferris RL. Tumor antigen-specific monoclonal antibodies and induction of T-cell immunity. Semin Oncol 2014;41:678-84. [PMID: 25440612 DOI: 10.1053/j.seminoncol.2014.08.003] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
70 Concha-Benavente F, Srivastava R, Ferrone S, Ferris RL. Immunological and clinical significance of HLA class I antigen processing machinery component defects in malignant cells. Oral Oncol 2016;58:52-8. [PMID: 27264839 DOI: 10.1016/j.oraloncology.2016.05.008] [Cited by in Crossref: 37] [Cited by in F6Publishing: 37] [Article Influence: 6.2] [Reference Citation Analysis]
71 Srivastava RM, Trivedi S, Concha-Benavente F, Gibson SP, Reeder C, Ferrone S, Ferris RL. CD137 Stimulation Enhances Cetuximab-Induced Natural Killer: Dendritic Cell Priming of Antitumor T-Cell Immunity in Patients with Head and Neck Cancer. Clin Cancer Res 2017;23:707-16. [PMID: 27496866 DOI: 10.1158/1078-0432.CCR-16-0879] [Cited by in Crossref: 69] [Cited by in F6Publishing: 49] [Article Influence: 11.5] [Reference Citation Analysis]
72 Khalil DN, Postow MA, Ibrahim N, Ludwig DL, Cosaert J, Kambhampati SR, Tang S, Grebennik D, Kauh JS, Lenz HJ, Flaherty KT, Hodi FS, Lawrence DP, Wolchok JD. An Open-Label, Dose-Escalation Phase I Study of Anti-TYRP1 Monoclonal Antibody IMC-20D7S for Patients with Relapsed or Refractory Melanoma. Clin Cancer Res 2016;22:5204-10. [PMID: 27797971 DOI: 10.1158/1078-0432.CCR-16-1241] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
73 Baysal H, De Pauw I, Zaryouh H, Peeters M, Vermorken JB, Lardon F, De Waele J, Wouters A. The Right Partner in Crime: Unlocking the Potential of the Anti-EGFR Antibody Cetuximab via Combination With Natural Killer Cell Chartering Immunotherapeutic Strategies. Front Immunol 2021;12:737311. [PMID: 34557197 DOI: 10.3389/fimmu.2021.737311] [Reference Citation Analysis]
74 Kinder M, Greenplate AR, Strohl WR, Jordan RE, Brezski RJ. An Fc engineering approach that modulates antibody-dependent cytokine release without altering cell-killing functions. MAbs 2015;7:494-504. [PMID: 25933349 DOI: 10.1080/19420862.2015.1022692] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 3.3] [Reference Citation Analysis]
75 Heft Neal ME, Haring CT, Mann JE, Brenner JC, Spector ME, Swiecicki PL. Novel Immunotherapeutic Approaches in Head and Neck Cancer. J Cancer Metastasis Treat 2019;5:76. [PMID: 32661502 DOI: 10.20517/2394-4722.2019.32] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
76 Wang Z, Martin D, Molinolo AA, Patel V, Iglesias-Bartolome R, Degese MS, Vitale-Cross L, Chen Q, Gutkind JS. mTOR co-targeting in cetuximab resistance in head and neck cancers harboring PIK3CA and RAS mutations. J Natl Cancer Inst 2014;106:dju215. [PMID: 25099740 DOI: 10.1093/jnci/dju215] [Cited by in Crossref: 64] [Cited by in F6Publishing: 73] [Article Influence: 8.0] [Reference Citation Analysis]
77 Deligne C, Milcent B, Josseaume N, Teillaud JL, Sibéril S. Impact of Depleting Therapeutic Monoclonal Antibodies on the Host Adaptive Immunity: A Bonus or a Malus? Front Immunol 2017;8:950. [PMID: 28855903 DOI: 10.3389/fimmu.2017.00950] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
78 Wang J, Gong M, Fan X, Huang D, Zhang J, Huang C. Autophagy-related signaling pathways in non-small cell lung cancer. Mol Cell Biochem 2021. [PMID: 34757567 DOI: 10.1007/s11010-021-04280-5] [Reference Citation Analysis]
79 Chung CH, Bonomi M, Steuer CE, Li J, Bhateja P, Johnson M, Masannat J, Song F, Hernandez-Prera JC, Wenig BM, Molina H, Farinhas JM, McMullen CP, Wadsworth JT, Patel KB, Kish JA, Muzaffar J, Kirtane K, Rocco JW, Schell MJ, Saba NF. Concurrent Cetuximab and Nivolumab as a Second-Line or beyond Treatment of Patients with Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results of Phase I/II Study. Cancers (Basel) 2021;13:1180. [PMID: 33803335 DOI: 10.3390/cancers13051180] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
80 McMichael EL, Benner B, Atwal LS, Courtney NB, Mo X, Davis ME, Campbell AR, Duggan MC, Williams K, Martin K, Levine K, Olaverria Salavaggione GN, Noel T, Ganju A, Uppati S, Paul B, Olencki T, Teknos TN, Savvides P, Tridandapani S, Byrd JC, Caligiuri MA, Liu SV, Carson WE 3rd. A Phase I/II Trial of Cetuximab in Combination with Interleukin-12 Administered to Patients with Unresectable Primary or Recurrent Head and Neck Squamous Cell Carcinoma. Clin Cancer Res 2019;25:4955-65. [PMID: 31142501 DOI: 10.1158/1078-0432.CCR-18-2108] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 3.7] [Reference Citation Analysis]
81 Trivedi S, Srivastava RM, Concha-Benavente F, Ferrone S, Garcia-Bates TM, Li J, Ferris RL. Anti-EGFR Targeted Monoclonal Antibody Isotype Influences Antitumor Cellular Immunity in Head and Neck Cancer Patients. Clin Cancer Res 2016;22:5229-37. [PMID: 27217441 DOI: 10.1158/1078-0432.CCR-15-2971] [Cited by in Crossref: 71] [Cited by in F6Publishing: 45] [Article Influence: 11.8] [Reference Citation Analysis]
82 Palyca P, Koshenkov VP, Mehnert JM. Developments in the treatment of locally advanced and metastatic squamous cell carcinoma of the skin: a rising unmet need. Am Soc Clin Oncol Educ Book 2014;:e397-404. [PMID: 24857130 DOI: 10.14694/EdBook_AM.2014.34.e397] [Cited by in Crossref: 15] [Cited by in F6Publishing: 3] [Article Influence: 2.1] [Reference Citation Analysis]
83 Fasano M, Della Corte CM, Di Liello R, Barra G, Sparano F, Viscardi G, Iacovino ML, Paragliola F, Famiglietti V, Ciaramella V, Cimmino F, Capasso M, Iolascon A, Sforza V, Morabito A, Maiello E, Ciardiello F, Morgillo F. Induction of natural killer antibody-dependent cell cytotoxicity and of clinical activity of cetuximab plus avelumab in non-small cell lung cancer. ESMO Open 2020;5:e000753. [PMID: 32912860 DOI: 10.1136/esmoopen-2020-000753] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
84 Forster MD, Devlin MJ. Immune Checkpoint Inhibition in Head and Neck Cancer. Front Oncol 2018;8:310. [PMID: 30211111 DOI: 10.3389/fonc.2018.00310] [Cited by in Crossref: 63] [Cited by in F6Publishing: 53] [Article Influence: 15.8] [Reference Citation Analysis]
85 Zandberg DP, Ferris RL. Window Studies in Squamous Cell Carcinoma of the Head and Neck: Values and Limits. Curr Treat Options Oncol 2018;19:68. [PMID: 30367283 DOI: 10.1007/s11864-018-0587-0] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 2.8] [Reference Citation Analysis]
86 Ausoni S, Boscolo-Rizzo P, Singh B, Da Mosto MC, Spinato G, Tirelli G, Spinato R, Azzarello G. Targeting cellular and molecular drivers of head and neck squamous cell carcinoma: current options and emerging perspectives. Cancer Metastasis Rev 2016;35:413-26. [PMID: 27194534 DOI: 10.1007/s10555-016-9625-1] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 5.2] [Reference Citation Analysis]
87 Lin YM, Sung WW, Hsieh MJ, Tsai SC, Lai HW, Yang SM, Shen KH, Chen MK, Lee H, Yeh KT, Chen CJ. High PD-L1 Expression Correlates with Metastasis and Poor Prognosis in Oral Squamous Cell Carcinoma. PLoS One 2015;10:e0142656. [PMID: 26562534 DOI: 10.1371/journal.pone.0142656] [Cited by in Crossref: 114] [Cited by in F6Publishing: 114] [Article Influence: 16.3] [Reference Citation Analysis]
88 Naranjo-Gomez M, Cahen M, Lambour J, Boyer-Clavel M, Pelegrin M. Immunomodulatory Role of NK Cells during Antiviral Antibody Therapy. Vaccines (Basel) 2021;9:137. [PMID: 33567792 DOI: 10.3390/vaccines9020137] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
89 Mata-molanes JJ, Rebollo-liceaga J, Martínez-navarro EM, Manzano RG, Brugarolas A, Juan M, Sureda M. Relevance of Fc Gamma Receptor Polymorphisms in Cancer Therapy With Monoclonal Antibodies. Front Oncol 2022;12:926289. [DOI: 10.3389/fonc.2022.926289] [Reference Citation Analysis]
90 Dietsch GN, Lu H, Yang Y, Morishima C, Chow LQ, Disis ML, Hershberg RM. Coordinated Activation of Toll-Like Receptor8 (TLR8) and NLRP3 by the TLR8 Agonist, VTX-2337, Ignites Tumoricidal Natural Killer Cell Activity. PLoS One 2016;11:e0148764. [PMID: 26928328 DOI: 10.1371/journal.pone.0148764] [Cited by in Crossref: 35] [Cited by in F6Publishing: 31] [Article Influence: 5.8] [Reference Citation Analysis]
91 Merlano MC, Abbona A, Denaro N, Garrone O. Knowing the tumour microenvironment to optimise immunotherapy. Acta Otorhinolaryngol Ital 2019;39:2-8. [PMID: 30936573 DOI: 10.14639/0392-100X-2481] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
92 Rizell M, Sternby Eilard M, Andersson M, Andersson B, Karlsson-Parra A, Suenaert P. Phase 1 Trial With the Cell-Based Immune Primer Ilixadencel, Alone, and Combined With Sorafenib, in Advanced Hepatocellular Carcinoma. Front Oncol. 2019;9:19. [PMID: 30719425 DOI: 10.3389/fonc.2019.00019] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 6.0] [Reference Citation Analysis]
93 Sacchetti B, Botticelli A, Pierelli L, Nuti M, Alimandi M. CAR-T with License to Kill Solid Tumors in Search of a Winning Strategy. Int J Mol Sci 2019;20:E1903. [PMID: 30999624 DOI: 10.3390/ijms20081903] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 4.3] [Reference Citation Analysis]
94 Borrero-Palacios A, Cebrián A, Gómez Del Pulgar MT, García-Carbonero R, Garcia-Alfonso P, Aranda E, Elez E, López-López R, Cervantes A, Valladares M, Nadal C, Viéitez JM, Guillén-Ponce C, Rodríguez J, Hernández I, García JL, Vega-Bravo R, Puime-Otin A, Martínez-Useros J, Del Puerto-Nevado L, Rincón R, Rodríguez-Remírez M, Rojo F, García-Foncillas J. Combination of KIR2DS4 and FcγRIIa polymorphisms predicts the response to cetuximab in KRAS mutant metastatic colorectal cancer. Sci Rep 2019;9:2589. [PMID: 30796344 DOI: 10.1038/s41598-019-39291-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
95 Cw. Wong K, Johnson D, Hui EP, Ct. Lam R, By. Ma B, Tc. Chan A. Opportunities and Challenges in Combining Immunotherapy and Radiotherapy in Head and Neck Cancers. Cancer Treatment Reviews 2022. [DOI: 10.1016/j.ctrv.2022.102361] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
96 Karlsson-Parra A, Kovacka J, Heimann E, Jorvid M, Zeilemaker S, Longhurst S, Suenaert P. Ilixadencel - an Allogeneic Cell-Based Anticancer Immune Primer for Intratumoral Administration. Pharm Res 2018;35:156. [PMID: 29904904 DOI: 10.1007/s11095-018-2438-x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
97 Ferris RL, Licitra L, Fayette J, Even C, Blumenschein G Jr, Harrington KJ, Guigay J, Vokes EE, Saba NF, Haddad R, Ramkumar S, Russell J, Brossart P, Tahara M, Colevas AD, Concha-Benavente F, Lynch M, Li L, Gillison ML. Nivolumab in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: Efficacy and Safety in CheckMate 141 by Prior Cetuximab Use. Clin Cancer Res 2019;25:5221-30. [PMID: 31239321 DOI: 10.1158/1078-0432.CCR-18-3944] [Cited by in Crossref: 51] [Cited by in F6Publishing: 30] [Article Influence: 17.0] [Reference Citation Analysis]
98 Klöss S, Chambron N, Gardlowski T, Weil S, Koch J, Esser R, Pogge von Strandmann E, Morgan MA, Arseniev L, Seitz O, Köhl U. Cetuximab Reconstitutes Pro-Inflammatory Cytokine Secretions and Tumor-Infiltrating Capabilities of sMICA-Inhibited NK Cells in HNSCC Tumor Spheroids. Front Immunol 2015;6:543. [PMID: 26579120 DOI: 10.3389/fimmu.2015.00543] [Cited by in Crossref: 16] [Cited by in F6Publishing: 19] [Article Influence: 2.3] [Reference Citation Analysis]
99 Ming Lim C, Stephenson R, Salazar AM, Ferris RL. TLR3 agonists improve the immunostimulatory potential of cetuximab against EGFR+ head and neck cancer cells. Oncoimmunology 2013;2:e24677. [PMID: 23894722 DOI: 10.4161/onci.24677] [Cited by in Crossref: 32] [Cited by in F6Publishing: 31] [Article Influence: 3.6] [Reference Citation Analysis]
100 Lei Y, Kansy BA, Li J, Cong L, Liu Y, Trivedi S, Wen H, Ting JP, Ouyang H, Ferris RL. EGFR-targeted mAb therapy modulates autophagy in head and neck squamous cell carcinoma through NLRX1-TUFM protein complex. Oncogene 2016;35:4698-707. [PMID: 26876213 DOI: 10.1038/onc.2016.11] [Cited by in Crossref: 32] [Cited by in F6Publishing: 32] [Article Influence: 5.3] [Reference Citation Analysis]
101 Bossi P, Platini F. Radiotherapy plus EGFR inhibitors: synergistic modalities. Cancers Head Neck 2017;2:2. [PMID: 31093349 DOI: 10.1186/s41199-016-0020-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
102 Califano JA, Khan Z, Noonan KA, Rudraraju L, Zhang Z, Wang H, Goodman S, Gourin CG, Ha PK, Fakhry C, Saunders J, Levine M, Tang M, Neuner G, Richmon JD, Blanco R, Agrawal N, Koch WM, Marur S, Weed DT, Serafini P, Borrello I. Tadalafil augments tumor specific immunity in patients with head and neck squamous cell carcinoma. Clin Cancer Res 2015;21:30-8. [PMID: 25564570 DOI: 10.1158/1078-0432.CCR-14-1716] [Cited by in Crossref: 97] [Cited by in F6Publishing: 67] [Article Influence: 13.9] [Reference Citation Analysis]
103 Niemann J, Woller N, Brooks J, Fleischmann-Mundt B, Martin NT, Kloos A, Knocke S, Ernst AM, Manns MP, Kubicka S, Wirth TC, Gerardy-Schahn R, Kühnel F. Molecular retargeting of antibodies converts immune defense against oncolytic viruses into cancer immunotherapy. Nat Commun 2019;10:3236. [PMID: 31324774 DOI: 10.1038/s41467-019-11137-5] [Cited by in Crossref: 22] [Cited by in F6Publishing: 25] [Article Influence: 7.3] [Reference Citation Analysis]
104 Lu Y, Shi Y, You J. Strategy and clinical application of up-regulating cross presentation by DCs in anti-tumor therapy. J Control Release 2021;341:184-205. [PMID: 34774890 DOI: 10.1016/j.jconrel.2021.11.011] [Reference Citation Analysis]
105 Concha-Benavente F, Kansy B, Moskovitz J, Moy J, Chandran U, Ferris RL. PD-L1 Mediates Dysfunction in Activated PD-1+ NK Cells in Head and Neck Cancer Patients. Cancer Immunol Res 2018;6:1548-60. [PMID: 30282672 DOI: 10.1158/2326-6066.CIR-18-0062] [Cited by in Crossref: 55] [Cited by in F6Publishing: 44] [Article Influence: 13.8] [Reference Citation Analysis]
106 Vacchelli E, Vitale I, Eggermont A, Fridman WH, Fučíková J, Cremer I, Galon J, Tartour E, Zitvogel L, Kroemer G. Trial watch: Dendritic cell-based interventions for cancer therapy. Oncoimmunology. 2013;2:e25771. [PMID: 24286020 DOI: 10.4161/onci.25771] [Cited by in Crossref: 85] [Cited by in F6Publishing: 81] [Article Influence: 9.4] [Reference Citation Analysis]
107 Li Z, Liu Y, Fang X, Shu Z. Nanomaterials Enhance the Immunomodulatory Effect of Molecular Targeted Therapy. Int J Nanomedicine 2021;16:1631-61. [PMID: 33688183 DOI: 10.2147/IJN.S290346] [Reference Citation Analysis]
108 Riaz N, Morris LG, Lee W, Chan TA. Unraveling the molecular genetics of head and neck cancer through genome-wide approaches. Genes Dis. 2014;1:75-86. [PMID: 25642447 DOI: 10.1016/j.gendis.2014.07.002] [Cited by in Crossref: 62] [Cited by in F6Publishing: 50] [Article Influence: 7.8] [Reference Citation Analysis]
109 Zhang X, Ashcraft KA, Betof Warner A, Nair SK, Dewhirst MW. Can Exercise-Induced Modulation of the Tumor Physiologic Microenvironment Improve Antitumor Immunity? Cancer Res 2019;79:2447-56. [PMID: 31068341 DOI: 10.1158/0008-5472.CAN-18-2468] [Cited by in Crossref: 19] [Cited by in F6Publishing: 12] [Article Influence: 6.3] [Reference Citation Analysis]
110 Sasada T, Azuma K, Ohtake J, Fujimoto Y. Immune Responses to Epidermal Growth Factor Receptor (EGFR) and Their Application for Cancer Treatment. Front Pharmacol 2016;7:405. [PMID: 27833557 DOI: 10.3389/fphar.2016.00405] [Cited by in Crossref: 28] [Cited by in F6Publishing: 30] [Article Influence: 4.7] [Reference Citation Analysis]
111 Garrido G, Rabasa A, Garrido C, Chao L, Garrido F, García-Lora ÁM, Sánchez-Ramírez B. Upregulation of HLA Class I Expression on Tumor Cells by the Anti-EGFR Antibody Nimotuzumab. Front Pharmacol 2017;8:595. [PMID: 29056908 DOI: 10.3389/fphar.2017.00595] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 3.8] [Reference Citation Analysis]
112 Miyauchi S, Kim SS, Pang J, Gold KA, Gutkind JS, Califano JA, Mell LK, Cohen EEW, Sharabi AB. Immune Modulation of Head and Neck Squamous Cell Carcinoma and the Tumor Microenvironment by Conventional Therapeutics. Clin Cancer Res 2019;25:4211-23. [PMID: 30814108 DOI: 10.1158/1078-0432.CCR-18-0871] [Cited by in Crossref: 30] [Cited by in F6Publishing: 24] [Article Influence: 10.0] [Reference Citation Analysis]
113 Whiteside TL. Head and Neck Carcinoma Immunotherapy: Facts and Hopes. Clin Cancer Res 2018;24:6-13. [PMID: 28751445 DOI: 10.1158/1078-0432.CCR-17-1261] [Cited by in Crossref: 38] [Cited by in F6Publishing: 31] [Article Influence: 7.6] [Reference Citation Analysis]
114 Chester C, Ambulkar S, Kohrt HE. 4-1BB agonism: adding the accelerator to cancer immunotherapy. Cancer Immunol Immunother 2016;65:1243-8. [PMID: 27034234 DOI: 10.1007/s00262-016-1829-2] [Cited by in Crossref: 76] [Cited by in F6Publishing: 66] [Article Influence: 12.7] [Reference Citation Analysis]
115 Rouwendal GJ, van der Lee MM, Meyer S, Reiding KR, Schouten J, de Roo G, Egging DF, Leusen JH, Boross P, Wuhrer M, Verheijden GF, Dokter WH, Timmers M, Ubink R. A comparison of anti-HER2 IgA and IgG1 in vivo efficacy is facilitated by high N-glycan sialylation of the IgA. MAbs 2016;8:74-86. [PMID: 26440530 DOI: 10.1080/19420862.2015.1102812] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 2.7] [Reference Citation Analysis]
116 Wang W, Erbe AK, Hank JA, Morris ZS, Sondel PM. NK Cell-Mediated Antibody-Dependent Cellular Cytotoxicity in Cancer Immunotherapy. Front Immunol. 2015;6:368. [PMID: 26284063 DOI: 10.3389/fimmu.2015.00368] [Cited by in Crossref: 199] [Cited by in F6Publishing: 222] [Article Influence: 28.4] [Reference Citation Analysis]
117 Jie HB, Srivastava RM, Argiris A, Bauman JE, Kane LP, Ferris RL. Increased PD-1+ and TIM-3+ TILs during Cetuximab Therapy Inversely Correlate with Response in Head and Neck Cancer Patients. Cancer Immunol Res 2017;5:408-16. [PMID: 28408386 DOI: 10.1158/2326-6066.CIR-16-0333] [Cited by in Crossref: 47] [Cited by in F6Publishing: 32] [Article Influence: 9.4] [Reference Citation Analysis]
118 Ou D, Adam J, Garberis I, Blanchard P, Nguyen F, Levy A, Casiraghi O, Gorphe P, Breuskin I, Janot F, Temam S, Scoazec JY, Deutsch E, Tao Y. Clinical relevance of tumor infiltrating lymphocytes, PD-L1 expression and correlation with HPV/p16 in head and neck cancer treated with bio- or chemo-radiotherapy. Oncoimmunology 2017;6:e1341030. [PMID: 28932643 DOI: 10.1080/2162402X.2017.1341030] [Cited by in Crossref: 20] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
119 de Lima PO, Joseph S, Panizza B, Simpson F. Epidermal Growth Factor Receptor's Function in Cutaneous Squamous Cell Carcinoma and Its Role as a Therapeutic Target in the Age of Immunotherapies. Curr Treat Options Oncol 2020;21:9. [PMID: 32016630 DOI: 10.1007/s11864-019-0697-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
120 Charap AJ, Enokida T, Brody R, Sfakianos J, Miles B, Bhardwaj N, Horowitz A. Landscape of natural killer cell activity in head and neck squamous cell carcinoma. J Immunother Cancer 2020;8:e001523. [PMID: 33428584 DOI: 10.1136/jitc-2020-001523] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
121 Boland PM, Ma WW. Immunotherapy for Colorectal Cancer. Cancers (Basel). 2017;9. [PMID: 28492495 DOI: 10.3390/cancers9050050] [Cited by in Crossref: 77] [Cited by in F6Publishing: 63] [Article Influence: 15.4] [Reference Citation Analysis]
122 Pahl JHW, Cerwenka A, Ni J. Memory-Like NK Cells: Remembering a Previous Activation by Cytokines and NK Cell Receptors. Front Immunol 2018;9:2796. [PMID: 30546366 DOI: 10.3389/fimmu.2018.02796] [Cited by in Crossref: 23] [Cited by in F6Publishing: 26] [Article Influence: 5.8] [Reference Citation Analysis]
123 Economopoulou P, Kotsantis I, Psyrri A. Checkpoint Inhibitors in Head and Neck Cancer: Rationale, Clinical Activity, and Potential Biomarkers. Curr Treat Options Oncol. 2016;17:40. [PMID: 27315066 DOI: 10.1007/s11864-016-0419-z] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 3.4] [Reference Citation Analysis]
124 Trivedi S, Concha-Benavente F, Srivastava RM, Jie HB, Gibson SP, Schmitt NC, Ferris RL. Immune biomarkers of anti-EGFR monoclonal antibody therapy. Ann Oncol 2015;26:40-7. [PMID: 24997207 DOI: 10.1093/annonc/mdu156] [Cited by in Crossref: 24] [Cited by in F6Publishing: 27] [Article Influence: 3.0] [Reference Citation Analysis]
125 Dréau D, Moore LJ, Wu M, Roy LD, Dillion L, Porter T, Puri R, Momin N, Wittrup KD, Mukherjee P. Combining the Specific Anti-MUC1 Antibody TAB004 and Lip-MSA-IL-2 Limits Pancreatic Cancer Progression in Immune Competent Murine Models of Pancreatic Ductal Adenocarcinoma. Front Oncol 2019;9:330. [PMID: 31114758 DOI: 10.3389/fonc.2019.00330] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
126 Juliá EP, Mordoh J, Levy EM. Cetuximab and IL-15 Promote NK and Dendritic Cell Activation In Vitro in Triple Negative Breast Cancer. Cells 2020;9:E1573. [PMID: 32605193 DOI: 10.3390/cells9071573] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
127 Srivastava RM, Marincola FM, Shanker A. Editorial: Lymphocyte Functional Crosstalk and Regulation. Front Immunol 2019;10:2916. [PMID: 31921175 DOI: 10.3389/fimmu.2019.02916] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
128 Mahmood J, Shukla HD, Soman S, Samanta S, Singh P, Kamlapurkar S, Saeed A, Amin NP, Vujaskovic Z. Immunotherapy, Radiotherapy, and Hyperthermia: A Combined Therapeutic Approach in Pancreatic Cancer Treatment. Cancers (Basel). 2018;10. [PMID: 30486519 DOI: 10.3390/cancers10120469] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 4.5] [Reference Citation Analysis]
129 Wittrup KD. Antitumor Antibodies Can Drive Therapeutic T Cell Responses. Trends Cancer 2017;3:615-20. [PMID: 28867165 DOI: 10.1016/j.trecan.2017.07.001] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 3.6] [Reference Citation Analysis]
130 Kersh AE, Ng S, Chang YM, Sasaki M, Thomas SN, Kissick HT, Lesinski GB, Kudchadkar RR, Waller EK, Pollack BP. Targeted Therapies: Immunologic Effects and Potential Applications Outside of Cancer. J Clin Pharmacol 2018;58:7-24. [PMID: 29136276 DOI: 10.1002/jcph.1028] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
131 Bauman JE, Cohen E, Ferris RL, Adelstein DJ, Brizel DM, Ridge JA, O'Sullivan B, Burtness BA, Butterfield LH, Carson WE, Disis ML, Fox BA, Gajewski TF, Gillison ML, Hodge JW, Le QT, Raben D, Strome SE, Lynn J, Malik S. Immunotherapy of head and neck cancer: Emerging clinical trials from a National Cancer Institute Head and Neck Cancer Steering Committee Planning Meeting. Cancer 2017;123:1259-71. [PMID: 27906454 DOI: 10.1002/cncr.30449] [Cited by in Crossref: 36] [Cited by in F6Publishing: 35] [Article Influence: 6.0] [Reference Citation Analysis]
132 Concha-Benavente F, Srivastava RM, Trivedi S, Lei Y, Chandran U, Seethala RR, Freeman GJ, Ferris RL. Identification of the Cell-Intrinsic and -Extrinsic Pathways Downstream of EGFR and IFNγ That Induce PD-L1 Expression in Head and Neck Cancer. Cancer Res 2016;76:1031-43. [PMID: 26676749 DOI: 10.1158/0008-5472.CAN-15-2001] [Cited by in Crossref: 151] [Cited by in F6Publishing: 106] [Article Influence: 21.6] [Reference Citation Analysis]
133 Lu S, Concha-Benavente F, Shayan G, Srivastava RM, Gibson SP, Wang L, Gooding WE, Ferris RL. STING activation enhances cetuximab-mediated NK cell activation and DC maturation and correlates with HPV+ status in head and neck cancer. Oral Oncol 2018;78:186-93. [PMID: 29496049 DOI: 10.1016/j.oraloncology.2018.01.019] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 5.3] [Reference Citation Analysis]
134 Tinhofer I, Budach V, Jöhrens K, Keilholz U. The rationale for including immune checkpoint inhibition into multimodal primary treatment concepts of head and neck cancer. Cancers Head Neck 2016;1:8. [PMID: 31093338 DOI: 10.1186/s41199-016-0009-6] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
135 Bowles DW, Keysar SB, Eagles JR, Wang G, Glogowska MJ, McDermott JD, Le PN, Gao D, Ray CE, Rochon PJ, Roop DR, Tan AC, Serracino HS, Jimeno A. A pilot study of cetuximab and the hedgehog inhibitor IPI-926 in recurrent/metastatic head and neck squamous cell carcinoma. Oral Oncol. 2016;53:74-79. [PMID: 26705064 DOI: 10.1016/j.oraloncology.2015.11.014] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 3.1] [Reference Citation Analysis]
136 Kohrt HE, Colevas AD, Houot R, Weiskopf K, Goldstein MJ, Lund P, Mueller A, Sagiv-Barfi I, Marabelle A, Lira R, Troutner E, Richards L, Rajapaska A, Hebb J, Chester C, Waller E, Ostashko A, Weng WK, Chen L, Czerwinski D, Fu YX, Sunwoo J, Levy R. Targeting CD137 enhances the efficacy of cetuximab. J Clin Invest 2014;124:2668-82. [PMID: 24837434 DOI: 10.1172/JCI73014] [Cited by in Crossref: 131] [Cited by in F6Publishing: 80] [Article Influence: 16.4] [Reference Citation Analysis]
137 Moynihan KD, Irvine DJ. Roles for Innate Immunity in Combination Immunotherapies. Cancer Res 2017;77:5215-21. [PMID: 28928130 DOI: 10.1158/0008-5472.CAN-17-1340] [Cited by in Crossref: 47] [Cited by in F6Publishing: 25] [Article Influence: 9.4] [Reference Citation Analysis]
138 Wang S, Zhang Y, Wang Y, Ye P, Li J, Li H, Ding Q, Xia J. Amphiregulin Confers Regulatory T Cell Suppressive Function and Tumor Invasion via the EGFR/GSK-3β/Foxp3 Axis. J Biol Chem 2016;291:21085-95. [PMID: 27432879 DOI: 10.1074/jbc.M116.717892] [Cited by in Crossref: 50] [Cited by in F6Publishing: 40] [Article Influence: 8.3] [Reference Citation Analysis]
139 Wise-Draper TM, Bahig H, Karivedu V, Burtness B. Current Therapy for Metastatic Head and Neck Cancer: Evidence, Opportunities, and Challenges. Am Soc Clin Oncol Educ Book 2022;42:1-14. [PMID: 35486888 DOI: 10.1200/EDBK_350442] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
140 Luo HS, Xu HY, Du ZS, Li XY, Wu SX, Huang HC, Lin LX. Prognostic Significance of Baseline Neutrophil Count and Lactate Dehydrogenase Level in Patients With Esophageal Squamous Cell Cancer Treated With Radiotherapy. Front Oncol 2020;10:430. [PMID: 32351882 DOI: 10.3389/fonc.2020.00430] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
141 Gildener-Leapman N, Lee J, Ferris RL. Tailored immunotherapy for HPV positive head and neck squamous cell cancer. Oral Oncol 2014;50:780-4. [PMID: 24126224 DOI: 10.1016/j.oraloncology.2013.09.010] [Cited by in Crossref: 25] [Cited by in F6Publishing: 18] [Article Influence: 2.8] [Reference Citation Analysis]
142 Berszin M, Michaelides I, Siemert J, Röhl L, Wellhausen J, Wald T, Bohr C, Künzel J, Gradistanac T, Dietz A, Zebralla V, Pirlich M, Wiegand S, Wichmann G. Cytokine Profiles of Head and Neck Squamous Cell Carcinoma Undergoing Dual Immunotherapy With Cetuximab and Pembrolizumab Identify Interferon Gamma-Induced Protein 10 as Novel Biomarker. Front Oncol 2022;12:795277. [DOI: 10.3389/fonc.2022.795277] [Reference Citation Analysis]
143 Bauman JE, Ferris RL. Integrating novel therapeutic monoclonal antibodies into the management of head and neck cancer. Cancer 2014;120:624-32. [PMID: 24222079 DOI: 10.1002/cncr.28380] [Cited by in Crossref: 37] [Cited by in F6Publishing: 31] [Article Influence: 4.1] [Reference Citation Analysis]
144 Cheng Y, Borcherding N, Ogunsakin A, Lemke-Miltner CD, Gibson-Corley KN, Rajan A, Choi AB, Wongpattaraworakul W, Chan CHF, Salem AK, Weiner GJ, Simons AL. The anti-tumor effects of cetuximab in combination with VTX-2337 are T cell dependent. Sci Rep 2021;11:1535. [PMID: 33452311 DOI: 10.1038/s41598-020-80957-z] [Reference Citation Analysis]
145 Nersesian S, Schwartz SL, Grantham SR, MacLean LK, Lee SN, Pugh-Toole M, Boudreau JE. NK cell infiltration is associated with improved overall survival in solid cancers: A systematic review and meta-analysis. Transl Oncol 2021;14:100930. [PMID: 33186888 DOI: 10.1016/j.tranon.2020.100930] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 5.5] [Reference Citation Analysis]
146 Wang X, Muzaffar J, Kirtane K, Song F, Johnson M, Schell MJ, Li J, Yoder SJ, Conejo-Garcia JR, Guevara-Patino JA, Bonomi M, Bhateja P, Rocco JW, Steuer CE, Saba NF, Chung CH. T cell repertoire in peripheral blood as a potential biomarker for predicting response to concurrent cetuximab and nivolumab in head and neck squamous cell carcinoma. J Immunother Cancer 2022;10:e004512. [PMID: 35676062 DOI: 10.1136/jitc-2022-004512] [Reference Citation Analysis]